Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE versus ZIPAN 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE versus ZIPAN 50.
PROPOXYPHENE HYDROCHLORIDE vs ZIPAN-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene hydrochloride is a centrally acting opioid analgesic that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of and response to pain.
ZIPAN-50 (zinc acetate) is a dietary supplement that provides zinc, an essential trace element. Zinc acts as a cofactor for numerous enzymes, including those involved in DNA synthesis, cell division, and immune function. It also stabilizes cell membranes and has antioxidant properties.
65 mg orally every 4 hours as needed for pain; maximum 390 mg per day.
50 mg orally once daily
None Documented
None Documented
6–12 hours (parent drug); norpropoxyphene metabolite half-life 30–36 hours, accumulates with repeated dosing, increasing risk of toxicity, especially in elderly or renal impairment.
Terminal elimination half-life is 4 hours (range 3-5 hours) in patients with normal renal function; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (70-90% as unchanged drug and metabolites, including norpropoxyphene); biliary/fecal excretion accounts for less than 10%.
Renal excretion of unchanged drug accounts for approximately 60%, with 30% as glucuronide conjugate. Biliary/fecal elimination contributes 10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic